|1.28 0.03 (2.4%)||12-06 16:00|
|Targets||6-month :||1.59||1-year :||1.8|
|Resists||First :||1.36||Second :||1.54|
|Supports||First :||1.05||Second :||0.88|
|MAs||MA(5) :||1.25||MA(20) :||1.25|
|MA(100) :||2.12||MA(250) :||2.6|
|MACD||MACD :||-0.1||Signal :||-0.1|
|%K %D||K(14,3) :||61.6||D(3) :||54|
|52-week||High :||4.59||Low :||1.02|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTSO ] has closed below upper band by 35.6%. Bollinger Bands are 48.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
|If tomorrow:||Open lower||Open higher|
|High:||1.39 - 1.4||1.4 - 1.41|
|Low:||1.2 - 1.21||1.21 - 1.22|
|Close:||1.27 - 1.28||1.28 - 1.29|
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Thu, 09 Nov 2023
CytoSorbents: Q3 Earnings Snapshot - Manistee News Advocate
Thu, 09 Nov 2023
CytoSorbents: Q3 Earnings Snapshot - Quartz
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||44 (M)|
|Shares Float||37 (M)|
|Held by Insiders||9.3 (%)|
|Held by Institutions||38.6 (%)|
|Shares Short||1,680 (K)|
|Shares Short P.Month||1,620 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0.41|
|Profit Margin||-63.3 %|
|Operating Margin||-81.4 %|
|Return on Assets (ttm)||-32.1 %|
|Return on Equity (ttm)||-81.4 %|
|Qtrly Rev. Growth||8.6 %|
|Gross Profit (p.s.)||0.46|
|Sales Per Share||0.83|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-21 (M)|
|Levered Free Cash Flow||-13 (M)|
|Price to Book value||3.04|
|Price to Sales||1.53|
|Price to Cash Flow||-2.77|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|